Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic (PK) Exposure of 4-Hydroxycyclophosphamide Associates with Clinical Benefits of Reduced-Dose Post-Transplantation Cyclophosphamide: Results of a Completed Phase I/II Trial to De-Escalate Post-Transplantation Cyclophosphamide for HLA-Haploidentical Myeloablative Bone Marrow Transplantation

Blood (2024) 144 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2024-212138

Published: 2024

Journal Articles

Characteristics and Risk Factors for BK Virus-Associated Cystitis after Post-Transplant Cyclophosphamide (PTCy) -Based Allogeneic Hematopoietic Cell Transplants (HCT)

Elisabetta Xue, Dimana Dimitrova, Hyoyoung Choo-Wosoba, Rechache Kamil, Ruby Sabina, Christi McKeown, Alison Cusmano, Mustafa A. Hyder, Christopher G. Kanakry, Jennifer A. Kanakry

Blood (2024) 144 (Supplement 1): 689.

https://doi.org/10.1182/blood-2024-208193

Published: 2024

Journal Articles

Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Cynthia Eleanya, Stacey Doran, Amy Chai, Rebecca Schwartz, Jessica Andrade, Dimana Dimitrova, Jennifer Hendricks, Mustafa A. Hyder, Rechache Kamil, Ruby Sabina, Jennifer Sponaugle, Christopher G. Kanakry, Jennifer A. Kanakry

Blood (2024) 144 (Supplement 1): 2429.

https://doi.org/10.1182/blood-2024-205625

Published: 2024

Journal Articles

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects

Michael T. Patterson, Shanzay M. Khan, Natalia S. Nunes, Rochelle E. Fletcher, Jing Bian, Ashley D. Hadjis, Michael A. Eckhaus, Suresh K. Mendu, Alessandra de Paula Pohl, David J. Venzon, Hyoyoung Choo-Wosoba, Kazusa Ishii, Haiying Qin, Terry J. Fry, Maggie Cam, Christopher G. Kanakry

Blood (2023) 141 (6): 659–672.

https://doi.org/10.1182/blood.2022016660

Published: 2023

Includes: Supplemental data

Journal Articles

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Shannon R. McCurdy, Vedran Radojcic, Hua-Ling Tsai, Ante Vulic, Elizabeth Thompson, Sanja Ivcevic, Christopher G. Kanakry, Jonathan D. Powell, Brian Lohman, Djamilatou Adom, Sophie Paczesny, Kenneth R. Cooke, Richard J. Jones, Ravi Varadhan, Heather J. Symons, Leo Luznik

Blood (2022) 139 (4): 608–623.

https://doi.org/10.1182/blood.2021013054

Published: 2022

Includes: Supplemental data

Journal Articles

Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation

Meredith J. McAdams, Mustafa Hyder, Dimana Dimitrova, Jennifer L. Sadler, Christi McKeown, Seth M. Steinberg, Amy Chai, Scott Napier, Anita Stokes, Jennifer Sponaugle, Thomas E. Hughes, Nu Ri Cha, Jennifer Cuellar-Rodriguez, Melissa Walker, Ronald E. Gress, Jennifer A. Kanakry, Christopher G. Kanakry

Blood (2021) 138 (Supplement 1): 101.

https://doi.org/10.1182/blood-2021-146997

Published: 2021

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Blood (2021) 137 (23): 3291–3305.

https://doi.org/10.1182/blood.2020009362

Published: 2021

Includes: Supplemental data

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137221

Published: 2020

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

https://doi.org/10.1182/blood-2019-125865

Published: 2019

Journal Articles

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Blood (2018) 132 (Supplement 1): 1015.

https://doi.org/10.1182/blood-2018-99-110814

Published: 2018

Journal Articles

Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide

Shannon R. McCurdy, MD, Christopher G. Kanakry, MD, Hua-Ling Tsai, ScM, Javier Bolaños-Meade, MD, Ephraim J. Fuchs, MD MBA, Gary Rosner, ScD, Richard J. Jones, MD, Leo Luznik, MD

Blood (2017) 130 (Supplement 1): 216.

https://doi.org/10.1182/blood.V130.Suppl_1.216.216

Published: 2017

Journal Articles

Post-Transplantation Cyclophosphamide Induces Alloreactive T-Cell Functional Impairment and Depends on Foxp3 + Regulatory T Cells Not Selective Elimination or Intrathymic Clonal Deletion of Alloreactive T Cells

Lucas P. Wachsmuth, Michael T. Patterson, Michael A. Eckhaus, DVM, Ronald E. Gress, MD, Christopher G. Kanakry, MD

Blood (2017) 130 (Supplement 1): 4433.

https://doi.org/10.1182/blood.V130.Suppl_1.4433.4433

Published: 2017

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

Journal Articles

The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis

Sarah A. Buckley, MD, Brent L. Wood, MD PhD, Megan Othus, PhD, Christopher S. Hourigan, MD PhD, Celalettin Ustun, MD, Michael A. Linden, MD PhD, Todd E. DeFor, MS, Michele Malagola, MD PhD, Christopher G. Kanakry, MD, Bernd Gruhn, MD, Beth Devine, PhD PharmD, Roland B. Walter, MD PhD

Blood (2016) 128 (22): 2842.

https://doi.org/10.1182/blood.V128.22.2842.2842

Published: 2016

Journal Articles

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

Jacqueline W. Mays, DDS, MHSc, PhD, Lauren M. Curtis, MD, Carol Bassim, DMD, MS, Seth M. Steinberg, PhD, David Venzon, PhD, Jeremy J. Rose, MS, Monica Cho, Christopher G. Kanakry, MD, Fahd Yazdanie, Daniele Avila, NP, Kristin Baird, MD, Jennifer Hsu, RN, Licia Masuch, George Grimes, RPh, Judith Starling, RPh, Daniel H. Fowler, MD, Ronald E. Gress, MD, Fran T. Hakim, PhD, Steven Z. Pavletic, MD

Blood (2016) 128 (22): 826.

https://doi.org/10.1182/blood.V128.22.826.826

Published: 2016

Journal Articles

Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Hanna A. Knaus, MD, Raúl Montiel-Esparza, MD, Joshua F. Zeidner, MD, Amanda Blackford, ScM, Christopher G. Kanakry, MD, Ante Vulic, MD, Mark J. Levis, MD PhD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2015) 126 (23): 3849.

https://doi.org/10.1182/blood.V126.23.3849.3849

Published: 2015

Journal Articles

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Blood (2015) 125 (19): 3024–3031.

https://doi.org/10.1182/blood-2015-01-623991

Published: 2015

Includes: Supplemental data

Journal Articles

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Blood (2014) 124 (25): 3817–3827.

https://doi.org/10.1182/blood-2014-07-587477

Published: 2014

Includes: Supplemental data

Journal Articles

Characterization of Immune Evasion Mechanisms at Diagnosis and after Chemotherapy in Patients with Acute Myeloid Leukemia

Hanna A. Knaus, MD, Joshua F. Zeidner, MD, Raul Montiel Esparza, MD, Christopher G. Kanakry, Sudipto Ganguly, PhD, Ante Vulic, MD, Amanda Blackford, MS, B. Douglas Smith, MD, Judith E. Karp, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2014) 124 (21): 1065.

https://doi.org/10.1182/blood.V124.21.1065.1065

Published: 2014

NARROW

Characteristics and Risk Factors for BK Virus-Associated Cystitis after Post-Transplant Cyclophosphamide (PTCy) -Based Allogeneic Hematopoietic Cell Transplants (HCT)

Understanding Barriers to Hematopoietic Cell Transplant (HCT) Access: Socio-Demographic Characteristics and Area Deprivation Index (ADI) of Patients Referred to the National Institutes of Health (NIH) for HCT

Murine allogeneic CAR T cells integrated before or early after posttransplant cyclophosphamide exert antitumor effects

Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning

Phase I/II Study of Reduced Dosing of Post-Transplantation Cyclophosphamide (PTCy) after HLA-Haploidentical Bone Marrow Transplantation

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

Grade II Acute Gvhd Improves Progression-Free Survival after Myeloablative HLA-Matched Bone Marrow Transplant with Posttransplantation Cyclophosphamide

Post-Transplantation Cyclophosphamide Induces Alloreactive T-Cell Functional Impairment and Depends on Foxp3 + Regulatory T Cells Not Selective Elimination or Intrathymic Clonal Deletion of Alloreactive T Cells

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis

A Randomized Phase 2 Placebo Controlled Trial of Clobetasol Rinse for Treatment of Oral Chronic Graft-Versus-Host Disease

Tracking Effector T Cell Dynamics and Immune Inhibitory Receptors in Patients with Acute Myeloid Leukemia (AML)

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

Characterization of Immune Evasion Mechanisms at Diagnosis and after Chemotherapy in Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only